Introduction
LGALS8, a member of the galectin family, serves as a prostate-specific antigen. Its overexpression is exclusively observed in malignant tumors, making it a valuable supplementary marker for identifying malignancies. LGALS8, similar to the selectin family within C-type lectins, mediates both cell-cell and cell-matrix interactions.
Description
Recombinant human LGALS8, produced in E. coli, is a single, non-glycosylated polypeptide chain. It comprises 337 amino acids (specifically, amino acids 1-317) and exhibits a molecular weight of 37.9 kDa. This LGALS8 protein is engineered with a 20 amino acid His-Tag at its N-terminus. Purification is achieved through proprietary chromatographic techniques.
Physical Appearance
The product is a sterile, colorless solution that has been filtered for sterility.
Formulation
The Galectin-8 His tag protein solution is supplied at a concentration of 0.5mg/ml. It is formulated in a buffer containing 20mM Tris-HCl (pH 8), 0.1M NaCl, 10% glycerol, and 1mM DTT.
Stability
For short-term storage (up to 2-4 weeks), the product should be kept at 4°C. For extended storage, it is recommended to store the product frozen at -20°C. To ensure optimal stability during long-term storage, consider adding a carrier protein like HSA or BSA (0.1%). It's important to minimize freeze-thaw cycles to maintain product integrity.
Purity
The purity of the protein is determined using SDS-PAGE analysis and is consistently greater than 90%.
Biological Activity
The biological activity of LGALS8 is assessed by its ability to agglutinate human red blood cells. The ED50 for this agglutination effect is in the range of 5-10 µg/ml. This corresponds to a specific activity of 100-200 IU/mg.
Synonyms
Gal-8, PCTA1, Po66-CBP, Prostate carcinoma tumor antigen 1.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MMLSLNNLQN IIYNPVIPFV GTIPDQLDPG TLIVIRGHVP SDADRFQVDL QNGSSMKPRA DVAFHFNPRF
KRAGCIVCNT LINEKWGREE ITYDTPFKRE KSFEIVIMVL KDKFQVAVNG KHTLLYGHRI GPEKIDTLGI YGKVNIHSIG FSFSSDLQST
QASSLELTEI SRENVPKSGT PQLRLPFAAR LNTPMGPGRT VVVKGEVNAN AKSFNVDLLA GKSKDIALHL NPRLNIKAFV RNSFLQESWG
EEERNITSFP FSPGMYFEMI IYCDVREFKV AVNGVHSLEY KHRFKELSSI DTLEINGDIH LLEVRSW.